These like mine are trading shares. After March most here will "blow this Popsicle stand", and yes our clowns who have taken years of losses are so proud of themselves, the reality is most retail is avg in 90-111 pennies Their return is not all that big the last 5 years. I am positive on Insmed but not convinced since they still have a very small pipeline. I do hope they score big on NTM - thats the whole ball game Good Luck
Thats ridiculous . A low float bio and you cant buy in 25k lots? - No kiddin!.
I own stocks with hundred of K shares and I didnt buy 4 -25k lots because 1- it doesnt happen in bio ( unless you have big liquidity). Its also a poor way to buy into any stock.........chasing. Good Luck
they breached the 50 day days ago and was a signal of more pain ( 18.20 ) your probably looking at the 200 day.I doubt they will go there. Traders just take what comes their way and adjust they dont say ! We're not going below 18 !!!!! terry is a basher!..............Good Luck
Re: "If you try buying shares, i'm sure you'll find them hard to come by ...
3 traders I chat with ( one being me ) bought 4200 shares all within a few minutes this morning. As my previous post stated, I suggesting anything below 16.50 (pivot). As they tried to push it down we threw them a couple extra pennies and voila~~ shares. Hope this helps.
Here's my Vote! . didnt like the $15.91 Call?
The fact that you do not understand WHY I posted that number makes you a clown ! LOL . ok surfs up!! 79 here in Southern California and I can smell the Ocean out my front door buh bye
by terry_insm Feb 8, 2014 "My original opinion was that the results would "need some additional work"
IMHO- Lewis has refined his act nicely (carefully worded ) today- 2017 is looking more realistic than mid year 2015 .
MIke - ignore the clowns during working hours. 2 trades today ... go back to where you once belonged - )
I tried to tell ya fellas ! ............ Chart now says: target is :
ps- look at the clowns responses ,just more nonsense without basis or knowledge...
I'm so amused,I'm laughing all the way to the Bank
Insmed just gave themselves a CYA timeframe. The review is NOT for approval but just to see if they can file.Insmed has adv because of its status.additional work was my call...we shall see Ok lots of good trades again and you know where we are
I posted about Wedbush many times on this board and examples of blcht ($15!! then rat data!! , No one forced anyone to sell their shares. Most analysts are basing their projections on NTM moving ahead to file because of the FDA being supportive. My USB post is supported by 2 public sites that published the $7 . Would Insmed have to do a dilution to support a Phase3 trial? and many here have OPINED that Insmed would be filing for a mid 2015 + launch.That was their opinion.......No that was a HOPE.There is risk of a Phase3 trial OR as I posted the company might have to ( as Will Lewis also said - "do additional work ( mine more data etc). The clowns like to pump and risk is something they are blinded to. Insmed has risks and if anything, today Wedbush slant maybe woke them up from their stupor
Yeah a complaint to the SEC (sic) will do a lot of good. It is Wedbushs OPINION.It may be a slanted one, it may be an accurate one ...a Phase3 trial is a very real Possibility which is wht Insmed has 2018 as a possibility also.
while you sell? LOL
The analyst believes expectations for Insmed's Ph II Nontuberculous Mycobacteria lung infection study are too high and the design suggests there will not be sufficient data for FDA approval and that a subsequent Ph III study will be needed. The firm's new launch date is mid-2018 vs previous expectations of early 2016 and the price target on shares has been reduced to $7 from $18
" Analyst Ratings News " .hmmm that was one of the sources of my UBS post.... Usually pretty good. and that was widely circulated also (31) Wedbushs we know is verifiable and probably blcht . The 1.1 M shares is very real. YES! I work for MMs lol !
ok last one ....we shall see ...........tomorrow will be interesting.
lets hope you are correct.The problem is signs - the cos mfg PR, more than likely Insmed is talking now with the FDA on a reg pathway,( and a possible source leak within the agency - this does happen) puts etc.
On the scam side is Wedbush who I have long posted here PRs one thing and does the opposite ( for those of you who remember BUY BUY BUY!! $!%!!!!! and then the rat data news killed INSM. Good Luck
surfs not up